We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

VAXIMM To Announce First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy in Combination with Avelumab

Product News   May 14, 2020

 
VAXIMM To Announce First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy in Combination with Avelumab
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Mission Bio Launches Cloud-based Tool to Improve CRISPR Safety

Product News

Mission Bio has extended capabilities for its automated, cloud-based tool for designing targeted single-cell DNA custom panels, now with applications across mouse genomes and CRISPR editing.

READ MORE

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Miltenyi Biotec Launches Fully Automated Light Sheet Microscope

Product News

Miltenyi Biotec has announced the UltraMicroscope Blaze, the world’s first fully automated light sheet microscope.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE